[go: up one dir, main page]

WO2015075221A1 - Système de récipient pour thérapie intraveineuse - Google Patents

Système de récipient pour thérapie intraveineuse Download PDF

Info

Publication number
WO2015075221A1
WO2015075221A1 PCT/EP2014/075379 EP2014075379W WO2015075221A1 WO 2015075221 A1 WO2015075221 A1 WO 2015075221A1 EP 2014075379 W EP2014075379 W EP 2014075379W WO 2015075221 A1 WO2015075221 A1 WO 2015075221A1
Authority
WO
WIPO (PCT)
Prior art keywords
container
drug
key
bottle
vial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/075379
Other languages
English (en)
Inventor
Thomas Norling
Shaun Phillips
Dave FAWKES
Bruce Renfrew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals ApS
Original Assignee
Xellia Pharmaceuticals ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals ApS filed Critical Xellia Pharmaceuticals ApS
Publication of WO2015075221A1 publication Critical patent/WO2015075221A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2089—Containers or vials which are to be joined to each other in order to mix their contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A61J1/1418—Threaded type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2006—Piercing means
    • A61J1/201—Piercing means having one piercing end
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2006—Piercing means
    • A61J1/2013—Piercing means having two piercing ends
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2031—Separating means having openings brought into alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2048—Connecting means
    • A61J1/2051—Connecting means having tap means, e.g. tap means activated by sliding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/20—Colour codes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/30—Printed labels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/40—General identification or selection means by shape or form, e.g. by using shape recognition

Definitions

  • Intravenous therapy is the infusion of liquid substances into a vein to deliver the substances throughout the body.
  • Intravenous therapy is widely used for medical care. For example, patients are prescribed an IV drip for correcting electrolyte imbalances, replacing lost fluids or providing an access route for delivery of IV medications.
  • Devices for intravenous therapy typically include a catheter, a sterile container of fluids, and a sterile tube.
  • a catheter is inserted through the skin into a vein.
  • a sterile container of fluids can be made of glass bottle, plastic bottle or plastic bag, and can have an attachment that allows the fluid to flow one drop at a time.
  • a sterile tube connects the catheter and the fluid container and can have a clamp to regulate or stop the flow of the fluid.
  • this disclosure is directed to a container system.
  • the container system is adapted for intravenous therapy.
  • Various aspects are described in this disclosure, which include, but are not limited to, the following aspects.
  • One aspect is a system comprising: a first container defining an interior sized to hold a drug composition, the first container including a first sterile port defining a key structure; and a second container defining an interior sized to hold a pharmaceutically acceptable composition, the second container including a second sterile port having a lock structure; wherein the key structure of the first container is sized to be mated with the lock structure of the second container to connect the first container to the second container when the drug composition in the first container is compatible with the pharmaceutically acceptable composition in the second container.
  • Another aspect is a method of reducing an occurrence of a medical error during administration of a drug to a patient.
  • the method comprises: assembling the aforementioned system; and administering the drug to a patient in need thereof.
  • the method involves a key-lock system coded to allow a certain dosage of a drug to only fit with a compatible dilutent type in a correct volume.
  • Some drugs for intravenous administration are produced in several dosages. It is crucial for patient safety to dilute the correct dosage in a correct volume of a compatible dilutent.
  • FIG. 1 is a schematic view of an example set of devices used for intravenous therapy.
  • FIG. 2 is a schematic, exploded view of an example container system according to the present disclosure.
  • FIG. 3 is a schematic, exploded view of the first container of FIG. 2.
  • FIG. 4 is a schematic, exploded view of the key structure of FIG. 3.
  • FIG. 5 is a schematic, exploded view of the second container of FIG. 2.
  • FIG. 6 is a schematic, exploded view of the lock structure of FIG. 5.
  • FIG. 7 is a schematic view of another example container system according to the present disclosure.
  • FIG. 8 is an exploded view of the container system of FIG. 7.
  • FIG. 9 is a schematic, exploded view of the first container of FIGS. 7 and 8.
  • FIG. 10 is a schematic, exploded view of the second container of FIGS. 7 and 8.
  • FIG. 11 is a schematic, exploded view of the ID connector of FIGS. 7 and 8.
  • FIG. 1 is a schematic view of an example system 100 used for intravenous therapy.
  • the system 100 includes a catheter 102, a tube 104 and a container system 106.
  • the catheter 102 is a tube that is inserted in a patient 108 to administer fluids into a vein of the body, for example.
  • the catheter 102 typically includes a needle portion, a plug and a protection cap.
  • the needle portion is actually inserted into the vein.
  • the needle portion is attached to the plug, which is connected to the tube 204.
  • the protection cap can be used to cover the needle portion.
  • Other configurations are possible, and the present disclosure is not so limited.
  • the tube 104 is configured to connect the catheter 102 and the container system 106 and deliver liquid medications from the container system 106 to a patient 108 via the catheter 102 inserted into the body of the patient 108.
  • the tube 104 is sterile and has a clamp to regulate or stop the flow of liquid medications.
  • the container system 106 is configured to contain liquid medications and provide the medications to a patient through the catheter 102.
  • the container system 106 is located higher than the catheter 102 inserted into a body of the patient 108 so that the liquid medications contained in the container system 106 flow through the tube 104 to the catheter 102 by gravity.
  • the container system 106 can further include a device that controls the flow of liquid medications by, for example, permitting the fluidic medications to flow one drop at a time or be delivered with positive pressure using a pump.
  • the container system 106 generally includes at least two components.
  • One component is a first container defining an interior sized to hold a drug composition.
  • Another component is a second container defining an interior sized to hold a pharmaceutically acceptable composition.
  • a keying structure is arranged between the first container and the second container.
  • the keying structure which can be carried by one or both of the first and second containers or be a separate component, assures that the drug composition held by the first container is introduced into a compatible
  • Compatibility of these materials can be measured based upon such criteria as the types of drugs (e.g., the correct drug composition is introduced into the correct pharmaceutically acceptable composition) and/or dosage (e.g., a proper amount of the drug composition is introduced into the pharmaceutically acceptable
  • the container system 106 includes a first container or vial 110 and a second container or dilution bottle [0026]
  • the vial 110 contains a drug composition 114 that is to be dissolved in a dilution solution or composition 116 contained in the dilution bottle 112.
  • the vial 110 is configured to be connected to the dilution bottle 112, a type of which is configured to be compatible with a predetermined type of the vial 110.
  • the vial 110 When connected to the dilution bottle 112, the vial 110 becomes in fluid communication with the dilution bottle 112, and thus allows the drug composition 114 contained in the vial 110 to flow or drop into the dilution bottle 112 and dissolve in the dilution solution or composition 116 contained in
  • the drug composition 114 can be any type of composition adapted for intravenous therapy, which includes, for example, a reconstituted drug product or a ready-to-use drug product.
  • the drug composition comprises an antifungal agent, an anti-bacterial agent, a sedative, an anesthetic, a pain reliever, an anti-cancer agent, or any drug product administered intravenously.
  • Non-exhaustive examples of the drug composition 114 include: Vancomycin, Ceftriaxone,
  • Ceftarolin Ceftazidim, Cefotaxim, Caspofungin, Micafungin, Cefuroxime,
  • Tazo/piperacillin Aztreonam, Doripenem, Ertapenem, Meropenem, Erythromycin, Clarithromycin, Azithromycin, Tigecyclin, CMS (i.e., a composition comprising sulfomethylated colistin), Voriconazole, Anidulafungin, Nafcillin, Teicoplanin, Dexmedetomidine, Propofol, Morphine, Fentanyl, and Irinotecan. A medical practitioner or clinician will know to consult the prescribing information associated with the drug product for purposes of administration to the patient.
  • the dilution bottle 112 contains the dilution solution or composition 116 that is to be mixed with the drug composition 114 contained in the vial 110.
  • the dilution bottle 112 is configured to accommodate only a predetermined type of the vial 110 so that the drug composition 114 contained in the vial 110 is mixed only with a pharmaceutically acceptable dilution solution or composition 116 contained in the dilution bottle 112.
  • the dilution bottle 112 can be any type of containers so long as it can hold the dilution solution or composition 116 therein.
  • the dilution bottle 112 is an infusion bag.
  • the dilution solution or composition 116 can be various types of solutions adapted for intravenous therapy.
  • Non-exhaustive examples of the composition 116 include: sterile saline solution, and crystalloid and colloid solutions.
  • FIG. 3 is a schematic, exploded view of the first container or vial 110 of FIG. 2.
  • the vial 110 includes an interior or vessel 120, a first sterile port 136, a vial label 126, and a vial seal 128.
  • the vessel 120 has an interior that is configured to hold the drug
  • the vessel 120 can contain different kinds of drug compositions 114 as necessary.
  • the vessel 120 can hold different volumes of drug compositions 114 as necessary.
  • the vessel 120 has a top end 130 and a bottom end 132 that is opposite to the top end. As explained in further detail below, the bottom end of the vessel 120 is engaged with an inlet 190 (see FIG. 5) of the dilution bottle 112 if the vessel 120 is successfully connected
  • the first sterile port 136 provides a passage for the drug composition 114 contained in the vessel 120 to flow into the dilution bottle 112 when the vial 110 is connected to a compatible type of the dilution bottle 112.
  • the first sterile port 136 includes an outlet 122, a first stopper 138 and a key structure 124.
  • the outlet 122 is formed on the vessel 120.
  • the outlet 122 is formed at the bottom end 132 of the vessel 120 so that the drug composition 114 held in the vessel 120 flows down or drops into the dilution bottle 112 when the vial 110 is vertically connected to the dilution bottle 112.
  • the first stopper 138 operates to seal the vessel 120 until the vial 110 is successfully connected to a compatible type of the dilution bottle 112.
  • the first stopper 138 is configured to seal the outlet 122 and thus sealingly contain the drug composition 114 within the vessel 120.
  • the first stopper 138 is torn or pierced by a piercing tube 216 (see FIG. 5) of the dilution bottle 112 so that the pierced first stopper 138 forms an aperture for the piercing tube 216 (see FIG. 5) to pass through to enter the vessel 120 via the outlet 122.
  • the first stopper 138 is made of a material that can be pierced and self-seals upon removal of the piercing device, such as a thermoplastic elastomer like Santoprene.
  • the outlet 122 has a mechanism for securing the key structure 124 with the outlet 122.
  • the mechanism includes a flange 134 formed around the circumference of the outlet 122 at the bottom end 132 of the vessel 120. The flange 134 is coupled with the key structure 124 and secures the key structure 124 at the bottom end 132 of the vessel 120 while the outlet 122 is aligned with a passage formed by the key structure 124.
  • the key structure 124 operates to match the vial 110 only with a compatible type of the dilution bottle 112. As explained below, the key structure 124 is configured to mate only with a particular type of a lock structure 196 (see FIG. 5) of the dilution bottle 112 and to be incompatible with other types of the lock structure 196 of the dilution bottle 112.
  • the vial label 126 is arranged to indicate several pieces of information.
  • the vial label 126 is designed to show a drug ID, a dilution ID and a bottle size ID.
  • the drug ID represents the kind of a drug composition 114 contained in the vessel 120.
  • the dilution ID shows the kind of a pharmaceutically acceptable composition or dilution solution 116 that is compatible with the drug composition 114 contained in the vessel 120.
  • the bottle size ID indicates the volume or dosage of the drug composition
  • the vial label 126 has three different color lines 142, 144 and 146 to represent the three different IDs, respectively.
  • the drug ID can be represented by the color line 142 (e.g., red color)
  • the dilution ID can be illustrated by the color line 144 (e.g., yellow color)
  • the bottle size ID can be distinguished by the color line 146 (e.g., blue color).
  • the information is written on the vial label 126. In still other embodiments, such written information is accompanied
  • the vial label 126 is attached around the outer surface of the key structure 124. In some embodiments, the vial label 126 is attached on the vessel 120.
  • the vial seal 128 operates to seal the first sterile port 136 until the vial 110 is used.
  • the vial seal 128 is sealingly attached to the bottom surface of the key structure 124 to seal a passage formed by the key structure 124 that is connected to the outlet 122.
  • the vial seal 128 is peeled off before the vial 110 is used with the dilution bottle 112.
  • FIG. 4 is a schematic, exploded view of the key structure 124 of FIG. 3.
  • the key structure 124 includes at least one female key element. The number of the female key elements varies depending on the number of identification (ID) information implemented for the container system 106, such as a drug composition (drug ID), a dilution composition (dilution ID), and a composition volume (bottle size ID).
  • ID identification
  • the female key elements are configured as at least one cylinder with a hollow, or through-going bore, formed along an axis of the cylinder.
  • the key structure 124 includes three female key elements or female hollow cylinders 152, 154 and 156 to represent three different pieces of ID information therein.
  • a first female key element or first female hollow cylinder 152 is configured to indicate the drug ID of the drug composition 114 contained in the vial 110.
  • a second female key element or second female hollow cylinder 154 is designed to represent the dilution ID.
  • a third female key element or third female hollow cylinder 156 operates to indicate the bottle size ID.
  • the female key elements of the key structure 124 are configured to have a prismatic shape, which is a uniform polyhedron with a multi- sided polygonal base.
  • a prismatic shape examples include a cuboid, a hexagonal prism and an octagonal prism.
  • the first female key element 152 is sized to accommodate the second female key element 154 within the hollow formed inside the first female key element 152.
  • the second female key element 154 is sized to accommodate the third female key element 156 within the hollow formed inside the second female key element 154.
  • the key structure 124 shown in FIG. 3 illustrates that the three female key elements 152, 154 and 156 are combined together.
  • the female key elements are fixed to one another in a predetermined manner so that the combination of the female key elements represents a particular combination of the drug ID, the dilution ID and the bottle size ID and indicates that the drug composition 114 contained in the vial 110 is intended to be used for a particular type of the dilution bottle 112.
  • the female key elements have keyways, respectively.
  • the first female key element has a first keyway
  • the second female key element has a second keyway
  • the third female key element has a third keyway.
  • the keyways operate to be mated with coupling keys of the lock structure 196 (see FIG. 5) when the drug composition 114 contained in the vial 110 is compatible with the dilution solution 116 contained in the dilution bottle 112.
  • the keyways are configured as at least one groove 162, 164 and 166 axially formed on the outer surface of the female hollow cylinders 152, 154 and 156, respectively, along the length thereof.
  • the grooves of the female hollow cylinders 152, 154 and 156 are arranged to be mated with projections 232, 234 and 236 of male key elements or male hollow cylinders 222, 224 and 226 (see FIG. 6) if the drug composition 114 contained in the vial 110 is compatible with the dilution solution 116 contained in the dilution bottle 112.
  • the first female hollow cylinder 152 has two first grooves 162
  • the second female hollow cylinder 154 has one second groove 164
  • the third female hollow cylinder 156 has two third grooves 166.
  • the grooves 162, 164 and 166 are used to implement variations of the ID information associated with the corresponding female key elements or female hollow cylinders, respectively.
  • the first grooves 162 are arranged to represent different kinds of the drug composition 114 (variations of the drug ID).
  • the second groove 164 is configured to indicate different kinds of the dilution solution 116 that is compatible with the drug composition 114 contained in the vessel 120 (variations of the dilution ID).
  • the third grooves 166 is arranged to implement different volumes or dosages of the drug composition 114 contained in the vessel 120 or different dilution solutions contained in the dilution bottle 112 (variations of the bottle size ID).
  • variations of each piece of ID information are implemented by changing the number of grooves formed on each female key element or female hollow cylinder 152, 154 or 156.
  • variations of each piece of information are made by changing the location of grooves formed on each female key element or female hollow cylinder 152, 154 or 156. For example, when there is a plurality of grooves 162 formed on the surface of the first female key element 152, the relative locations of the grooves 162 with respect to one another can represent different drug IDs.
  • the locations of the grooves formed in one female key element can be altered with respect to the locations of the grooves formed in another female key element in order to represent different kinds of the ID information (in this example, the drug ID, dilution ID or bottle size ID).
  • the groove 164 formed in the second female key element 154 can have different locations with respect to the grooves 162 of the first female key element 152 and/or with respect to the grooves 166 of the third female key element 156 so that such different relative locations represent
  • the female key elements are distinguished by different colors that can represent different pieces of ID information.
  • the vial label 126 has the three color lines 142, 144 and 146 to represent the drug ID, the dilution ID and the bottle size ID in this example, the first, second and third female key elements 152, 154 and 156 are configured to have red, yellow and blue colors, in part or as a whole, respectively.
  • FIG. 5 is a schematic, exploded view of the second container or dilution bottle 112 of FIG. 2.
  • the second container or dilution bottle 112 includes a reservoir 170, a second sterile port 172, a bottle seal 174 and a hanger 176.
  • the reservoir 170 has an interior that is configured to hold the dilution solution 116.
  • the reservoir 170 can contain different kinds or volumes of dilution solutions 116 as necessary.
  • the reservoir 170 has a top end 180 and a bottom end 182 that is opposite to the top end 180.
  • the reservoir 170 includes a supply port 184 at the bottom end 182 of the reservoir 170.
  • the supply port 184 is configured to be connected to the tube 104 to provide a passage to the tube 104 for a liquid medication that is made by mixing the drug composition 114 and the dilution solution 116.
  • the reservoir 170 includes a bottle label 186 to indicate ID information.
  • the bottle label 186 is designed to show the dilution ID and the bottle size ID.
  • the second sterile port 172 provides a passage for the drug composition 114, which has been contained in the vial 110, to drop or flow into the reservoir 170 of the dilution bottle 112 when the vial 110 is successfully connected to a compatible type of the dilution bottle 112.
  • the second sterile port 172 includes an inlet 190, a second stopper 192, a connector 194 and the lock structure 196.
  • the inlet 190 is formed on the reservoir 170. In some embodiments, the inlet 190 is formed at the top end 180 of the reservoir 170 so that the drug composition 114 flows down or drops into the dilution bottle 112 by gravity when the vial 110 is vertically connected to the dilution bottle 112.
  • the second stopper 192 operates to seal the reservoir 170 until the dilution bottle 112 is successfully coupled with a compatible type of the vial 110.
  • the second stopper 192 is configured to seal the inlet 190 and sealingly hold the dilution solution 116 within the reservoir 170.
  • the second stopper 192 is torn or pierced by a piercing tube 216 of the connector 194 so that the pierced second stopper 192 forms a passage for the drug composition 114 into the reservoir 170.
  • the second stopper 192 is made of a thermoplastic elastomer.
  • the inlet 190 has a mechanism for securing the connector 194 with the inlet 190.
  • the mechanism includes a female threaded portion 210 formed around the circumference of the inlet 190 at the top end 180 of the reservoir 170.
  • the female threaded portion 210 is coupled with a male threaded portion 212 of the connector 194 and secures the connector 194 at the top end 180 of the reservoir 170 while the inlet 190 is aligned with a passage formed by the connector 194.
  • the connector 194 operates to accommodate the lock structure 196 and receive the key structure 124 therein.
  • the connector 194 is configured to have its inner surface having a cross-section that is substantially identical to the cross section of the key structure 124 and/or the lock structure 196.
  • the connector 194 is adapted to have a cylindrical inner surface that can receive the key structure 124 and the lock structure 196 along the axis of the connector.
  • the connector 194 includes a male threaded portion 212, a base portion 214, a piercing tube 216 and a connector coupling key 218.
  • the male threaded portion 212 operates to couple the connector 194 to the inlet 190 of the reservoir 170.
  • the male threaded portion 212 is configured to be mated with the female threaded portion 210 at the top end 180 of the reservoir 170 while the inlet 190 is aligned with a passage formed by the piercing tube 216.
  • the base portion 214 is configured to be engaged with the top surface of the inlet 190 when the connector 194 is coupled to the inlet 190.
  • the base portion 214 is arranged right above the male threaded portion 212 so that there remains no space between the base portion 214 and the inlet 190 when the connector 194 is connected to the inlet 190.
  • the piercing tube 216 operates to pierce the first stopper 138 of the outlet 122 as the first sterile port 136 of the vial 110 is introduced into the second sterile port 172 of the dilution bottle 112. In some embodiments, the piercing tube 216 also operates to pierce the second stopper 192 of the inlet 190 when the vial 110 is successfully connected to a compatible type of the dilution bottle 112. The piercing tube 216 also provides a passage for the drug composition 114 from the vessel 120 into the reservoir 170 via the
  • the piercing tube 216 is fixed at the base portion 214 and extends from the base portion 214. In other embodiments, the piercing tube 216 is slidably engaged with the base portion 214 and displaceable with respect to the base portion 214 along a length of the connector 194.
  • the piercing tube 216 has a needle portion at the tip thereof so that the needle portion punctures the first stopper 138 of the outlet 122.
  • the piercing tube 216 can be configured to pierce the second stopper 192 of the inlet 190 downwardly as well as to pierce the first stopper 138 of the outlet 122.
  • the piercing tube 216 has a length greater than the height of the key structure 124 so that the piercing tube 216 passes through a passage formed by the key structure 124, and reaches and pierces the first stopper 138.
  • the connector coupling key 218 operates to receive and secure the lock structure 196 in place within the connector 194.
  • the connector coupling key 218 is configured to be mated with a second connector keyway 220 of the lock structure 196.
  • the connector coupling key 218 is arranged on the inner surface of the connector 194 and vertically along the length of the connector 194 from the base portion 214.
  • the connector coupling key 218 also operates to guide the key structure 124 along the connector 194 and receive the key structure 124 on the lock structure 196 within the connector 194 when the vial 110 is mated with the dilution bottle 112.
  • the key structure 124 has a first connector keyway 168 that is configured to be mated with the connector coupling key 218.
  • the first connector keyway 168 is formed on outer surface of the key structure
  • the lock structure 196 operates to match the dilution bottle 112 only with a compatible type of the vial 110.
  • the lock structure 196 is configured to mate only with a particular type of the key structure 124 of the vial 110 and to be incompatible with other types of the key structure 124.
  • the bottle seal 174 (see FIG. 2) of the dilution bottle 112 is to seal the second sterile port 172 before the dilution bottle 112 is used.
  • the bottle seal 174 closes the top portion of the connector 194 to seal the components inside the connector 194 and prevent the contamination of the components associated with the second sterile port 172.
  • the bottle seal 174 is peeled off before the dilution bottle 112 is
  • the hanger 176 of the dilution bottle 112 operates to hang the dilution bottle 112 in a higher location than the catheter 102 that is inserted through the skin of a patient.
  • the hanger 176 is hung on a stand.
  • the hanger 176 is made as a strip that can be attached to any location of the dilution bottle 112.
  • the hanger 176 is attached adjacent to the top portion of the connector 194 so that the dilution bottle 112 stands substantially vertically when dilution bottle 112
  • FIG. 6 is a schematic, exploded view of the lock structure 196 of FIG. 5.
  • the lock structure 196 includes at least one male key element.
  • the number of the male key elements depends on the number of the female key elements of the key structure 124. In some embodiments, the numbers of the male key elements and the female key elements are the same.
  • the male key elements are configured to be mated with the female key elements of the key structure 124, respectively.
  • the lock structure 196 includes three male key elements or male hollow cylinders 222, 224 and 226 to match with three female hollow cylinders 152, 154 and 156.
  • a first male key element or first male hollow cylinder 222 is configured to be mated with the first female key element or first female hollow cylinder 152, which indicates the drug ID.
  • a second male key element or second male hollow cylinder 224 is designed to be mated with the second female key element or second female hollow cylinder 154, which indicates the dilution ID.
  • a third male key element or third male hollow cylinder 226 is configured to be mated with the third female key element or third female hollow cylinder 156, which indicates the bottle size ID.
  • the corresponding male key elements are configured to have the same or similar shapes that allow the male key elements to be mated with the female key elements.
  • the first male key element 222 is sized to accommodate the second male key element 224 within the hollow formed inside the first male key element 222.
  • the second male key element 224 is sized to accommodate the third male key element 226 within the hollow formed inside the second male key element 224.
  • the lock structure 196 shown in FIG. 5 illustrates that the three male key elements 222, 224 and 226 are combined together.
  • the male key elements are fixed to one another in a predetermined manner so that the combination of the male key elements represents a particular combination of the drug ID, the dilution ID and the bottle size ID and indicates that the dilution bottle 112 is intended to be used for a particular type of the drug composition 114 contained in the vial 110.
  • the male key elements have coupling keys, respectively, which are mated with the keyways of the female key elements.
  • the coupling keys are configured as at least one projection 232, 234 and 236 axially extending from the circumference of the male hollow cylinders 222, 224 and 226, respectively.
  • the projections of the male hollow cylinders 222, 224 and 226 are arranged to be mated with the grooves 162, 164 and 166 of the female hollow cylinders 152, 154 and 156 if the drug composition 114 is compatible with the dilution solution 116.
  • the first male hollow cylinder 222 has two first projections 232
  • the second male hollow cylinder 224 has one second projection 234
  • the third male hollow cylinder 226 has two third projections 236.
  • the projections 232, 234 and 236 are used to implement variations of ID information, such as the drug ID, the dilution ID and the bottle size ID.
  • ID information such as the drug ID, the dilution ID and the bottle size ID.
  • variations of each piece of information can be implemented by changing the number and/or location of the projections formed on each male key element or male hollow cylinder 222, 224 and 226 in accordance with the corresponding grooves formed on each female key element or female hollow cylinder 152, 154 and 156.
  • the fact that the key structure 124 is successfully mated with the lock structure 196 indicates that the vial 110 has been properly chosen for a compatible type of the dilution bottle 112 in terms of the implemented ID information (in this example, the drug ID, the dilution ID and the bottle size ID).
  • the occurrence of a medical error can be significantly reduced during administration of a drug to a patient with intravenous therapy.
  • the male key elements are distinguished by different colors that can represent different pieces of ID information.
  • the vial label 126 has the three color lines 142, 144 and 146 to represent the drug ID, the dilution ID and the bottle size ID in this example, the first, second and third male key elements 222, 224 and 226 are configured to have red, yellow and blue colors, in part or as a whole, respectively.
  • the container system 106 includes an indicator for indicating that the first sterile port 136 of the vial 110 has been successfully mated with the second sterile port 172 of the dilution bottle 112.
  • the indicator is implemented with a ball 252.
  • the ball 252 is held adjacent to the inlet 190 and is configured to be dropped into the reservoir 170 when the first sterile port 136 is properly mated with the second sterile port 172.
  • the indicator is configured as the piercing tube 216. As shown in FIG.
  • part of the piercing tube 216 or 1216 can be displaced downwardly when the first sterile port 136 is properly mated with the second sterile port 172, in order to show that the drug composition has been properly added to the dilution solution.
  • the indicator can be any mechanical or electronic signal triggered by proper mating of the key-lock, including, but limited to release of a ball, release of a sound, release of a light etc.
  • FIG. 7 is a schematic view of another example container system 1000 according to the present disclosure.
  • FIG. 8 is an exploded view of the container system 1000 of FIG. 7.
  • Most components of the container system 1106 have the same or substantially similar configurations and operations as the container system 106. For clarity purposes, therefore, corresponding or like components of the container system 1106 are hereinafter explained briefly.
  • the container system 1106 includes a first container or vial 1110, a second container or dilution bottle 1112, and an identification (ID) connector 1118.
  • ID identification
  • the vial 1110 contains a drug composition 1114 that is to dissolve in a dilution solution or composition 1116 contained in the dilution bottle 1112, which is compatible with a predetermined type of the vial 1110.
  • the dilution bottle 1112 contains a dilution solution or composition 1116 that is to be mixed with the drug composition 1114 contained in the vial 1110.
  • the ID connector 1118 operates like the connector 194.
  • the ID connector 1118 operates as a separate component that has additional key structures.
  • the additional key structures of the ID connector 1118 are configured to be mated with both the vial 1110 and the dilution bottle 1112.
  • the ID connector 1118 is also configured to represent one piece of ID information regarding the drug composition 1114 (drug ID), the dilution solution (dilution ID) and the volume or dosage thereof (bottle size ID).
  • FIG. 9 is a schematic, exploded view of the first container or the vial 1110 of FIGS. 7 and 8.
  • the vial 1110 includes an interior or vessel 1120, a first sterile port 1136, a vial label 1126, and a vial seal 1128.
  • the vessel 1120 and the vial seal 1128 have the same structures as the vessel 120 and the vial seal 128.
  • the vial label 1126 is arranged just as the vial label 126, except that, in this example, the vial label 1126 is attached on the top surface of the vessel 1120 and used to indicate only one piece of ID information, which is the drug ID in this example. In some embodiments, of course, the vial label 1126 can be attached to any location of the vial 1110 and used to indicate more than one piece of information.
  • the first sterile port 1136 provides a passage for the drug composition 1114 contained in the vessel 1120 to flow into the dilution bottle 1112 when the vial 1110 is connected with a compatible type of the dilution bottle 1112.
  • the first sterile port 1136 includes an outlet 1122, a first stopper 1138 and a key structure 1124.
  • the outlet 1122 and the first stopper 1138 have the same configurations as the outlet 122 and the first stopper 138.
  • the key structure 1124 operates to match the vial 1110 only with a compatible type of the ID connector 1118. As explained below, the key structure 1124 is configured to mate only with a particular type of a vial-side key structure 1302 (see FIG. 11) of the ID connector 1118.
  • the key structure 1124 includes a female key element 1152.
  • the female key element 1152 is configured as a cylinder with a hollow formed along the axis of the cylinder.
  • the female key element or female hollow cylinder 1152 operates to represent a piece of ID information, such as one of the drug ID, the dilution ID and the bottle size ID.
  • the female key element 1152 is configured to indicate the drug ID.
  • the female key element 1152 of the key structure 1124 can be configured to have a different shape from a
  • the female key element 1152 has a keyway that operates to be mated with a coupling key of the vial-side key structure 1302 of the ID connector 1118.
  • the keyway is configured as at least one groove 1162 axially formed on the outer surface of the female hollow cylinder 1152 along the length thereof.
  • the grooves 1162 are arranged to be mated with ledgeportions 1306 (see FIG. 11) of the vial-side key structure 1302 of the ID connector 1118.
  • the female hollow cylinder 1152 has two grooves 1162.
  • FIG. 10 is a schematic, exploded view of the second container or dilution bottle 1112 of FIGS. 7 and 8.
  • the second container or dilution bottle 1112 includes a reservoir 1170, a second sterile port 1172 and a bottle seal 1174.
  • the reservoir 1170 and the bottle seal 1174 have the same or similar configurations as the reservoir 170 and the bottle seal 174.
  • the reservoir 1170 includes a supply port 1180 and a bottle label 1182, which correspond to the supply port 184 and the bottle label 186 in the first example.
  • the second sterile port 1172 operates the same as the second sterile port 172 of the first example, except that, unlike the connector 194 that was a part of the second sterile port 172, the ID connector 1118 can be configured as a separate component for the container system 1106.
  • the second sterile port 1172 includes an inlet 1190, a second stopper 1192, and a lock structure 1196.
  • the inlet 1190 and the second stopper 1192 have the same configuration as the inlet 190 and the second stopper 192 in the first example.
  • the inlet 1190 also has a mechanism for receiving and securing the ID connector 1118 thereon.
  • the mechanism includes a female threaded portion 1210 formed around the circumference of the inlet 1190 at the top end of the reservoir 1170.
  • the female threaded portion 1210 is coupled with a male threaded portion 1212 (see FIG. 11) of the ID connector 1118 and secures the ID connector 1118 at the top end of the reservoir 1170 while the inlet 1190 is aligned with a passage formed by the ID connector 1118.
  • the inlet 1190 can have different diameters to identify one of the information including the drug ID, the dilution ID and the bottle size ID.
  • the inlet 1190 is sized to implement variations of the bottle size ID.
  • the inlet 1190 has a predetermined diameter according to a volume of the dilution solution 1116 contained in the dilution bottle 1112.
  • the lock structure 1196 operates to match the dilution bottle 1112 only with a compatible type of the ID connector 1118. As explained below, the lock structure 1196 is configured to mate only with a particular type of a bottle-side key structure 1304 (see FIG. 11) of the ID connector 1118.
  • the lock structure 1196 includes a male key element.
  • the male key element 1222 is configured as a cylinder with a hollow formed along the axis of the cylinder.
  • the male key element or male hollow cylinder 1222 operates to represent a piece of information, such as one of the drug ID, the dilution ID and the bottle size ID.
  • the male key element 1222 is configured to indicate the dilution ID.
  • the male key element 1222 of the lock structure 1196 can be configured to have a different shape from a cylinder.
  • the male key element 1222 has a coupling key that operates to be mated with a keyway of the bottle-side key structure 1304 of the ID connector 1118.
  • the coupling key is configured as at least one ledge portion 1232 axially extending on the outer surface of the male key element 1222.
  • the ledge portions 1232 are arranged to be mated with the grooves 1308 (see FIG. 11) of the bottle-side key structure 1304 of the ID connector 1118.
  • the male hollow cylinder 1196 has two ledge portions 1232.
  • FIG. 11 is a schematic, exploded view of the ID connector 1118 of FIGS. 7 and 8.
  • the ID connector 1118 operates like the connector 194 in the first example, except that the ID connector 1118 is configured as a separate component of the container system 1106 and is also used as an identifier of one piece of ID
  • the ID connector 1118 is considered to be incorporated into the second sterile port 1172, just as the connector 194 of the first example.
  • the ID connector 1118 operates to receive the key structure 1124 and the lock structure 1196 into opposite ends of the ID connector 1118, respectively.
  • the ID connector 1118 includes a body 1316, an identification (ID) flange 1314, a base portion 1214, a piercing tube 1216, a vial- side key structure 1302, a bottle-side key structure 1304, a vial-side seal 1310, a bottle-side seal 1312, a connector label 1127 and a hanger 1176.
  • the body 1316 is configured to accommodate therein at least the base portion 1214, the piercing tube 1216, the vial-side key structure 1302 and the bottle- side key structure 1304.
  • the body 1316 is configured to have its inner surface having a cross-section that is substantially identical to the cross section of the key structure 1124, the lock structure 1196, the vial-side key structure 1302 and/or the bottleside key structure 1304.
  • the ID connector 1118 is adapted to have a cylindrical inner surface that can receive the key structure 1124, the lock structure 1196, the vial-side key structure 1302 and the bottle-side key structure 1304 along the axis of the ID connector.
  • the ID flange 1314 operates to identify one of the ID information such as the drug ID, the dilution ID and the bottle size ID, together with the inlet 1190.
  • the ID flange 1314 is configured to represent variations of the bottle size ID.
  • the ID flange is sized to have a diameter corresponding to the size of the inlet 1190.
  • the ID connector 1118 can be properly selected for a compatible type of the dilution bottle 1112 with a predetermined volume or dosage of the dilution solution 1116 or the drug composition 1114.
  • the ID flange 1314 has a male threaded portion 1212 formed on the inner circumferential surface of the ID flange 1314.
  • the male threaded portion 1212 operates to couple the ID connector 1118 to the inlet 1190 of the reservoir 1170.
  • the male threaded portion 1212 is configured to be mated with the female threaded portion 1210 at the top end of the reservoir 1170 while the inlet 1190 is aligned with a passage formed by the piercing tube 1216.
  • the base portion 1214 is configured to be engaged with, or located adjacent to, the vial-side key structure 1302 and the bottle-side key structure 1304 on opposite sides of the base portion 1214, respectively.
  • the piercing tube 1216 operates to pierce the first stopper 1138 of the outlet 1122 and the second stopper 1192 of the inlet 1190 when the vial 1110 is successfully connected to a compatible type of the dilution bottle 1112.
  • the piercing tube 1216 also provides a passage for the drug composition 1114 from the vessel 1120 into the reservoir 1170 via the outlet 1122 and the inlet 1190.
  • the piercing tube 1216 has needle portions at both tips of the piercing tube 1216 so that the needle portions puncture the first stopper 1138 and the second stopper 1192, respectively, as the first sterile port 1136 and the second sterile port 1172 are introduced into the ID connector 1118.
  • the piercing tube 1216 has a length greater than the height of the key structure 1124 on the upward side and a length greater than the height of the lock structure 1196 on the downward side so that the piercing tube 1216 reaches and pierces the first stopper 1138 and the second stopper 1192.
  • the vial-side key structure 1302 is configured to be mated with the key structure 1124 so as to confirm that the vial 1110 is properly selected for a compatible type of the ID connector 1118.
  • the combination of the vial-side key structure 1302 and the key structure 1124 is implemented to verify the drug ID.
  • the vial-side key structure 1302 is configured as a hollow cylinder.
  • the hollow cylinder 1302 has an outer diameter sized to be accommodated within the body 1316.
  • the vial-side key structure 1302 has a coupling key that operates to be mated with a key way of the key structure 1124.
  • the coupling key is configured as at least one ledge portion 1306 axially extending on the inner surface of the hollow cylinder 1302.
  • the ledge portions 1306 are configured and arranged to be mated with the grooves 1162 of the key structure 1124.
  • the bottle-side key structure 1304 is configured to be mated with the lock structure 1196 so as to confirm that the ID connector 1118 is properly selected for a compatible type of the dilution bottle 1112.
  • the combination of the bottle-side key structure 1304 and the lock structure 1196 is implemented to verify the dilution ID.
  • the bottle-side key structure 1304 is configured as a hollow cylinder.
  • the hollow cylinder 1304 has an outer diameter sized to be accommodated within the body 1316.
  • the bottle-side key structure 1304 has a key way that operates to be mated with a coupling key (the ledge portions 1232) of the lock structure 1196.
  • the keyway is configured as at least one groove 1308 axially extending on the inner surface of the hollow cylinder 1304.
  • the grooves 1308 are configured and arranged to be mated with the ledge portions 1232 of the lock structure 1196.
  • the vial-side seal 1310 is attached to the top end of the ID connector 1118 to seal the ID connector 1118.
  • the vial-side seal 1310 is peeled off when the ID connector 1118 is used with the vial 1110.
  • the bottle-side seal 1312 is attached to the bottom end of the ID connector 1118 to seal the ID connector 1118 together with the vial- side seal 1310.
  • the bottle-side seal 1312 is peeled off when the ID connector 1118 is connected to the dilution bottle 1112.
  • the connector label 1127 is arranged around the body 1316 of the ID connector 1118 in the same manner as the vial label 126 in the first example.
  • the hanger 1176 operates to hang the container system 1106 at a certain location, just as the hanger 176 in the first example.
  • the hanger 1176 is made as a strip that is attached adjacent to the top portion of the body 1316 of the ID connector 1118 so that the dilution bottle 1112 stands substantially vertically when the container system 1106 dangles from a stand, for example.
  • An additional embodiment is directed to a method of reducing an occurrence of a medical error during administration of a drug to a patient, which comprises: assembling a system and administering the drug to a patient in need thereof; wherein the system comprises a first container defining an interior sized to hold a drug composition, the first container including a first sterile port defining a key structure; and a second
  • the second container defining an interior sized to hold a pharmaceutically acceptable composition
  • the second container including a second sterile port having a lock structure; wherein the key structure of the first container is sized to be mated with the lock structure of the second container to connect the first container to the second container when the drug composition in the first container is compatible with the pharmaceutically acceptable composition in the second container.
  • Yet another embodiment is directed to a method of reducing an occurrence of a medical error during administration of a drug to a patient, which comprises: assembling a system and administering the drug to a patient in need thereof;
  • the system comprises a first container defining an interior sized to hold a drug composition, the first container including a first sterile port defining a key structure; and a second container defining an interior sized to hold a
  • the container including a second sterile port having a lock structure; wherein the key structure of the first container is sized to be mated with the lock structure of the second container to connect the first container to the second container when the drug composition in the first container is compatible with the pharmaceutically acceptable composition in the second container and wherein the drug comprises an anti-fungal agent, an anti-bacterial agent, a sedative, an anesthetic, a pain reliever, an anti-cancer agent.
  • the drug is selected from the group consisting of: Vancomycin, Ceftriaxone, Ceftarolin, Ceftazidim, Cefotaxim, Caspofungin, Micafungin,

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne un système pour thérapie intraveineuse. Le système comprend un premier récipient définissant un intérieur dimensionné pour contenir une composition de médicament. Le premier récipient comprend un premier orifice stérile définissant une structure de clé. Le système comprend en outre un second récipient définissant un intérieur dimensionné pour contenir une composition pharmaceutiquement acceptable. Le second récipient comprend un second orifice stérile ayant une structure de verrou. La structure de clé du premier récipient est dimensionnée pour être appariée à la structure de verrou du second récipient pour raccorder le premier récipient au second récipient lorsque la composition de médicament dans le premier récipient est compatible avec la composition pharmaceutiquement acceptable dans le second récipient.
PCT/EP2014/075379 2013-11-25 2014-11-24 Système de récipient pour thérapie intraveineuse Ceased WO2015075221A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908205P 2013-11-25 2013-11-25
US61/908,205 2013-11-25

Publications (1)

Publication Number Publication Date
WO2015075221A1 true WO2015075221A1 (fr) 2015-05-28

Family

ID=52000816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/075379 Ceased WO2015075221A1 (fr) 2013-11-25 2014-11-24 Système de récipient pour thérapie intraveineuse

Country Status (1)

Country Link
WO (1) WO2015075221A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177384A1 (fr) * 2015-05-06 2016-11-10 Kocher-Plastik Maschinenbau Gmbh Système de prélèvement de contenu de récipient
WO2016177383A1 (fr) * 2015-05-06 2016-11-10 Kocher-Plastik Maschinenbau Gmbh Système de prélèvement de contenu de récipient
US20180168930A1 (en) * 2016-12-16 2018-06-21 Boehringer Ingelheim Vetmedica Gmbh Container system and method
US10549886B2 (en) 2016-12-16 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Light member on a package to provide information to a user
EP3716955A4 (fr) * 2017-12-01 2021-12-15 Healthy Option Consulting Inc. Capsule de gel liquide à double chambre souple et procédé d'administration de compositions de cannabis sublinguale et ingérable

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335378A2 (fr) * 1988-03-31 1989-10-04 Nissho Corporation Récipient pour un liquide
US5152965A (en) * 1989-06-02 1992-10-06 Abbott Laboratories Two-piece reagent container assembly
US5762646A (en) * 1996-09-30 1998-06-09 Duxbury Scientific, Inc. Blood collection system and coupling
EP1219283A2 (fr) * 1997-12-04 2002-07-03 Baxter International Inc. Dispositif de reconstitution coulissant muni d'un joint étanche
WO2013054323A1 (fr) * 2011-10-11 2013-04-18 Medimop Medical Projects Ltd Ensemble soupape destiné à être utilisé avec un récipient de liquide et un flacon de médicament

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335378A2 (fr) * 1988-03-31 1989-10-04 Nissho Corporation Récipient pour un liquide
US5152965A (en) * 1989-06-02 1992-10-06 Abbott Laboratories Two-piece reagent container assembly
US5762646A (en) * 1996-09-30 1998-06-09 Duxbury Scientific, Inc. Blood collection system and coupling
EP1219283A2 (fr) * 1997-12-04 2002-07-03 Baxter International Inc. Dispositif de reconstitution coulissant muni d'un joint étanche
WO2013054323A1 (fr) * 2011-10-11 2013-04-18 Medimop Medical Projects Ltd Ensemble soupape destiné à être utilisé avec un récipient de liquide et un flacon de médicament

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177384A1 (fr) * 2015-05-06 2016-11-10 Kocher-Plastik Maschinenbau Gmbh Système de prélèvement de contenu de récipient
WO2016177383A1 (fr) * 2015-05-06 2016-11-10 Kocher-Plastik Maschinenbau Gmbh Système de prélèvement de contenu de récipient
US10675219B2 (en) 2015-05-06 2020-06-09 Kocher-Plastik Maschinenbau Gmbh Transfer system for containers
US10932990B2 (en) 2015-05-06 2021-03-02 Kocher-Plastik Maschinenbau Gmbh Transfer system for containers
US20180168930A1 (en) * 2016-12-16 2018-06-21 Boehringer Ingelheim Vetmedica Gmbh Container system and method
WO2018109081A1 (fr) * 2016-12-16 2018-06-21 Boehringer Ingelheim Vetmedica Gmbh Système et procédé destinés à des contenants
CN110072504A (zh) * 2016-12-16 2019-07-30 勃林格殷格翰维特梅迪卡有限公司 容器系统及方法
JP2020501714A (ja) * 2016-12-16 2020-01-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 容器システム及び方法
US10549886B2 (en) 2016-12-16 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Light member on a package to provide information to a user
US10966904B2 (en) 2016-12-16 2021-04-06 Boehringer Ingelheim Vetmedica Gmbh Container system and method
US20210220222A1 (en) * 2016-12-16 2021-07-22 Boehringer Ingelheim Vetmedica Gmbh Container system and method
EP3716955A4 (fr) * 2017-12-01 2021-12-15 Healthy Option Consulting Inc. Capsule de gel liquide à double chambre souple et procédé d'administration de compositions de cannabis sublinguale et ingérable

Similar Documents

Publication Publication Date Title
JP6931332B2 (ja) 鈍針安全薬剤送達システム
JP7201745B2 (ja) 注入アダプタ
AU2021229229B2 (en) Improved components of a fluid transfer apparatus
US10912898B1 (en) Tamper evident cap for medical fitting
US8267912B2 (en) Infusion bag with needleless access port
US11612687B2 (en) Drug delivery device
CN205626622U (zh) 与输液容器一起使用的液体转移装置
US5807312A (en) Bolus pump apparatus
CN103957987B (zh) 具有可塌缩式弹性隔膜配件的无针式连接器和对应的方法
EP1484082B1 (fr) Méthode et dispositif de transfert de fluide
US5169385A (en) Safety I. V. drug introducer set
JP5095727B2 (ja) 通気式注入アクセス装置
US11690994B1 (en) Modular medical connector
CN102844061B (zh) 药物输送系统
WO2008081424A2 (fr) Robinet d'arrêt amélioré pour l'administration de médicaments dans l'organisme d'un patient
US11697527B1 (en) Tamper evident closure assembly
WO2015075221A1 (fr) Système de récipient pour thérapie intraveineuse
US20060058741A1 (en) Infusion apparatus for infusion bags
KR20110003950A (ko) 약화사고 방지를 위한 주사액 혼합용 안전 소켓 및 이를 포함하는 수액 키트
KR20120087960A (ko) 의료용 용기의 커넥터 세트
WO2010029371A2 (fr) Dispositif médical
TW202428244A (zh) 藥物處理裝置
HK40051871A (en) Improved components of a fluid transfer apparatus
HK40051870A (en) Improved components of a fluid transfer apparatus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14805528

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14805528

Country of ref document: EP

Kind code of ref document: A1